Welcome to The Lung Cancer Sessions brought to you by the Video Journal of Oncology (VJOncology). This exclusive discussion features leading experts Solange Peters, Martin Reck, and Sanjay Popat who debate the most important learnings from ESMO 2020 Science Weekend in lung cancer.
The topics of discussion include advances in oncogene targeted therapy, post-operative radiotherapy in non-small cell lung cancer (NSCLC), and immuno-oncology (I-O) advances in NSCLC and small cell lung cancer (SCLC).
CROWN:
“So, the data are really impressive. But that there is some discrepancy between the use in daily clinic and the data, in particular when we talk we talk about tolerability.”
– Martin Reck
“At the moment, I’m not starting with frontline lorlatinib. For me, it’s a very good salvage agent. Particularly for intracranial disease, and frontline alectinib or brigatinib are very reasonable frontline options.”
– Sanjay Popat
ADAURA:
“Of course, osimertinib has a protective effect on the brain. But is it enough to complete the datasets, to convince everyone that all patients with EGFR-mutated tumors which are large enough or have lymph node invasion should receive osimertinib in adjuvant for three years?…So take-home message, you will discuss it with your patients at least if you have the opportunity to deliver the drug, Sanjay? Martin, Martin maybe not?”
– Solange Peters
“So this is really a landmark trial, and this is a trial which really changes our therapeutic access to management of stage III disease. And I think we really have to individualize our indication to use postoperative radiotherapy in selected patients.”
– Martin Reck
“I mean LungART I think is one of the most important trials that we have actually had presented for many years. All of us have been debating in our routine multidisciplinary meetings, postoperatively whether patients should have radiotherapy or not.”
– Sanjay Popat
“So for me, STIMULI is a fantastic study, it’s really set the field. This is the beginning of the chapter of limited-stage small cell lung cancer, I’m very much looking forward to more data as it comes through.”
– Sanjay Popat
“There is clearly a signal of survival in some patients. But we have looked for PD-L1, we have looked for TMB, they are not sufficient to describe this group of patients. So, we need a new idea.”
– Martin Reck
By choosing to continue, you are confirming that you are a healthcare professional
Keep up to date with all the latest news with our monthly newsletter